AngioDynamics, Inc. has reported its fiscal year 2026 first-quarter financial results, showcasing the company's continued momentum driven by a 26.1% growth in its med tech segment. Here are the specific financial changes from the prior year:
- Net sales for the first quarter of fiscal year 2026 were $75.7 million, representing a 12.2% increase compared to the prior-year quarter.
- Med tech net sales reached $35.3 million, marking a significant 26.1% increase from the prior-year period.
- Med device net sales were $40.4 million, indicating a 2.3% increase compared to the prior-year period.
- The company achieved a gross margin of 55.3%, which was higher by 90 basis points compared to the first quarter of fiscal 2025.
- Adjusted EBITDA for the first quarter of fiscal 2026 was $2.2 million, a notable improvement compared to the ($0.2) million reported in the first quarter of fiscal 2025.
- The company ended the fiscal 2026 first quarter with $38.8 million in cash and cash equivalents, ahead of expectations.
The company's president and CEO, Jim Clemmer, emphasized the strong momentum created in fiscal 2025 and highlighted the fourth consecutive quarter of med tech growth of over 20%, showcasing sustained profitable growth. The company also enrolled the first patients in both the Ambition BTK and Recover-AV trials and published Nanoknife Preserve study results in a leading European journal.
Looking ahead, AngioDynamics raised its full-year fiscal 2026 guidance for net sales, med tech net sales growth, adjusted EBITDA, and adjusted EPS. The company now expects increased net sales of $308 * $313 million, up from the previous guidance of $305 * $310 million. Additionally, the company raised its adjusted EBITDA guidance to $6.0 * $10.0 million, up from the previous $3.0 * $8.0 million.
The company continues to expect a $4.0 * $6.0 million impact from tariffs for the full fiscal year 2026, with all assumptions based on the current tariff situation as of October 2, 2025. AngioDynamics maintains a debt-free balance sheet and expects to be cash flow positive for the full year fiscal 2026.
This article provides a snapshot of AngioDynamics' financial performance, highlighting its growth in specific segments and key financial metrics, as well as its outlook for the remainder of fiscal year 2026. The market has reacted to these announcements by moving the company's shares -0.9% to a price of $11.07. Check out the company's full 8-K submission here.
